Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease
- ,
- ,
- Mayuko Takezaki,
- ,
- ,
- Betty S. Pace(corresponding author)
- ,
- ,
- Augusta University,
- ,
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Abstract
<p>Sickle cell disease (SCD) is a pathophysiological condition of chronic hemolysis, oxidative stress, and elevated inflammation. The transcription factor Nrf2 is a master regulator of oxidative stress. Here, we report that the FDA-approved oral agent simvastatin, an inhibitor of hydroxymethyl-glutaryl coenzyme A reductase, significantly activates the expression of Nrf2 and antioxidant enzymes. Simvastatin also induces fetal hemoglobin expression in SCD patient primary erythroid progenitors and a transgenic mouse model. Simvastatin alleviates SCD symptoms by decreasing hemoglobin S sickling, oxidative stress, and inflammatory stress in erythroblasts. Particularly, simvastatin increases cellular levels of cystine, the precursor for the biosynthesis of the antioxidant reduced glutathione, and decreases the iron content in SCD mouse spleen and liver tissues. Mechanistic studies suggest that simvastatin suppresses the expression of the critical histone methyltransferase enhancer of zeste homolog 2 to reduce both global and gene-specific histone H3 lysine 27 trimethylation. These chromatin structural changes promote the assembly of transcription complexes to fetal γ-globin and antioxidant gene regulatory regions in an antioxidant response element-dependent manner. In summary, our findings suggest that simvastatin activates fetal hemoglobin and antioxidant protein expression, modulates iron and cystine/reduced glutathione levels to improve the phenotype of SCD, and represents a therapeutic strategy for further development.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Article number
337Journal (Volume, Issue Number)
Antioxidants (Volume 13, Issue 3)Publication milestones
- Published - 03/2024
Publication status
Published - 03/2024
Publication IDs
- Scopus: 85188663506
Publication metrics
Metrics
Fractional count
6
Fractional count
0.86
Fractional count
1
Fractional count
0.14
Fractional count
6
Fractional count
1
PlumX, opens in new tab
Mentions
2
Citation count
7
Captures
5
Funding Details
This research was funded by the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases R01DK119762 and R01DK139694 (X.Z.), the Augusta University Intramural Pilots Project (IGPP00055) (X.Z. and B.P.), and the National Heart, Lung, and Blood Institute R01HL149365 (B.P.).
